Literature DB >> 23355033

Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.

Srinevas K Reddy1, Omar Hyder, J Wallis Marsh, Georgios C Sotiropoulos, Andreas Paul, Sorin Alexandrescu, Hugo Marques, Carlo Pulitano, Eduardo Barroso, Luca Aldrighetti, David A Geller, Christine Sempoux, Vlad Herlea, Irinel Popescu, Robert Anders, Laura Rubbia-Brandt, Jean-Francois Gigot, Giles Mentha, Timothy M Pawlik.   

Abstract

BACKGROUND AND AIMS: The objective of this report was to determine the prevalence of underlying nonalcoholic steatohepatitis in resectable intrahepatic cholangiocarcinoma.
METHODS: Demographics, comorbidities, clinicopathologic characteristics, surgical treatments, and outcomes from patients who underwent resection of intrahepatic cholangiocarcinoma at one of eight hepatobiliary centers between 1991 and 2011 were reviewed.
RESULTS: Of 181 patients who underwent resection for intrahepatic cholangiocarcinoma, 31 (17.1 %) had underlying nonalcoholic steatohepatitis. Patients with nonalcoholic steatohepatitis were more likely obese (median body mass index, 30.0 vs. 26.0 kg/m(2), p < 0.001) and had higher rates of diabetes mellitus (38.7 vs. 22.0 %, p = 0.05) and the metabolic syndrome (22.6 vs. 10.0 %, p = 0.05) compared with those without nonalcoholic steatohepatitis. Presence and severity of hepatic steatosis, lobular inflammation, and hepatocyte ballooning were more common among nonalcoholic steatohepatitis patients (all p < 0.001). Macrovascular (35.5 vs. 11.3 %, p = 0.01) and any vascular (48.4 vs. 26.7 %, p = 0.02) tumor invasion were more common among patients with nonalcoholic steatohepatitis. There were no differences in recurrence-free (median, 17.0 versus 19.4 months, p = 0.42) or overall (median, 31.5 versus 36.3 months, p = 0.97) survival after surgical resection between patients with and without nonalcoholic steatohepatitis.
CONCLUSIONS: Nonalcoholic steatohepatitis affects up to 20 % of patients with resectable intrahepatic cholangiocarcinoma.

Entities:  

Mesh:

Year:  2013        PMID: 23355033      PMCID: PMC4007003          DOI: 10.1007/s11605-013-2149-x

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

1.  Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications.

Authors:  Felix Stickel; Claus Hellerbrand
Journal:  Gut       Date:  2010-07-21       Impact factor: 23.059

Review 2.  An overview of nonalcoholic steatohepatitis: past, present and future directions.

Authors:  Alina Pascale; Raluca Pais; Vlad Ratziu
Journal:  J Gastrointestin Liver Dis       Date:  2010-12       Impact factor: 2.008

3.  Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.

Authors:  Zobair M Younossi; Maria Stepanova; Mariam Afendy; Yun Fang; Youssef Younossi; Hesham Mir; Manirath Srishord
Journal:  Clin Gastroenterol Hepatol       Date:  2011-03-25       Impact factor: 11.382

Review 4.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection.

Authors:  Brad Q Starley; Christopher J Calcagno; Stephen A Harrison
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

5.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

6.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings.

Authors:  Elizabeth M Brunt; David E Kleiner; Laura A Wilson; Patricia Belt; Brent A Neuschwander-Tetri
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

7.  Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C.

Authors:  Katsutoshi Tokushige; Etsuko Hashimoto; Satoru Yatsuji; Maki Tobari; Makiko Taniai; Nobuyuki Torii; Keiko Shiratori
Journal:  J Gastroenterol       Date:  2010-04-08       Impact factor: 7.527

Review 8.  Prevalence, gender, ethnic variations, and prognosis of NASH.

Authors:  Etsuko Hashimoto; Katsutoshi Tokushige
Journal:  J Gastroenterol       Date:  2010-09-16       Impact factor: 7.527

9.  Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.

Authors:  Kohichiroh Yasui; Etsuko Hashimoto; Yasuji Komorizono; Kazuhiko Koike; Shigeki Arii; Yasuharu Imai; Toshihide Shima; Yoshihiro Kanbara; Toshiji Saibara; Takahiro Mori; Sumio Kawata; Hirofumi Uto; Shiro Takami; Yoshio Sumida; Toshinari Takamura; Miwa Kawanaka; Takeshi Okanoue
Journal:  Clin Gastroenterol Hepatol       Date:  2011-02-12       Impact factor: 11.382

10.  Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.

Authors:  Vlad Ratziu; Luminita Bonyhay; Vincent Di Martino; Frederic Charlotte; Lucas Cavallaro; Marie-Hélène Sayegh-Tainturier; Philippe Giral; André Grimaldi; Pierre Opolon; Thierry Poynard
Journal:  Hepatology       Date:  2002-06       Impact factor: 17.425

View more
  12 in total

1.  Short- and Long-Term Outcomes of Liver Resection for Intrahepatic Cholangiocarcinoma Associated with the Metabolic Syndrome.

Authors:  Christian Hobeika; François Cauchy; Nicolas Poté; Pierre-Emmanuel Rautou; François Durand; Olivier Farges; Safi Dokmak; Valérie Vilgrain; Maxime Ronot; Valérie Paradis; Olivier Soubrane
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

2.  Prevalence and relevance of nonalcoholic fatty liver disease in patients with primary sclerosing cholangitis.

Authors:  Iliana Doycheva; Kristen Cox; Abdul Haseeb; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2014-07       Impact factor: 3.199

Review 3.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

4.  Association of nonalcoholic fatty liver disease and liver cancer.

Authors:  Perla Oliveira Schulz; Fabio Gonçalves Ferreira; Maria de Fátima Araújo Nascimento; Andrea Vieira; Mauricio Alves Ribeiro; André Ibrahim David; Luiz Arnaldo Szutan
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

5.  Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models.

Authors:  Alexandre Doussot; Bas Groot-Koerkamp; Jimme K Wiggers; Joanne Chou; Mithat Gonen; Ronald P DeMatteo; Peter J Allen; T Peter Kingham; Michael I D'Angelica; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2015-04-24       Impact factor: 6.113

6.  Outcomes of Hepatic Resection in Intrahepatic Cholangiocarcinoma Patients with Diabetes, Hypertension, and Dyslipidemia: Significance of Routine Follow-Up.

Authors:  Takayoshi Nishioka; Shoji Kubo; Shogo Tanaka; Kenichi Wakasa; Shigekazu Takemura; Masahiko Kinoshita; Genya Hamano; Yuko Kuwae; Toshihiko Shibata; Shigefumi Suehiro
Journal:  Liver Cancer       Date:  2016-03-17       Impact factor: 11.740

7.  Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

Authors:  Jian Feng; Bin Liang; Hang-Yu Zhang; Zhe Liu; Kai Jiang; Xiang-Qian Zhao
Journal:  World J Gastrointest Surg       Date:  2022-05-27

8.  Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.

Authors:  Eliza W Beal; Dmitry Tumin; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Mary Dilhoff; Carl M Schmidt; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

Review 9.  Multidisciplinary Care of Patients with Intrahepatic Cholangiocarcinoma: Updates in Management.

Authors:  Kelly J Lafaro; David Cosgrove; Jean-Francois H Geschwind; Ihab Kamel; Joseph M Herman; Timothy M Pawlik
Journal:  Gastroenterol Res Pract       Date:  2015-05-19       Impact factor: 2.260

Review 10.  Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies.

Authors:  Giovanni Brandi; Andrea Farioli; Annalisa Astolfi; Guido Biasco; Simona Tavolari
Journal:  Oncotarget       Date:  2015-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.